Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprocitentan dose-finding in essential hypertension
NCT02603809Phase 2Completed
- Sponsor
- Idorsia
- Start
- Dec 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of aprocitentan in essential hypertension (6 arms), sponsored by Idorsia. Primary endpoint: Sitting Diastolic Blood Pressure at Trough at Day 56. Started Dec 2015; status: completed.
02
Drugs
aprocitentan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT02603809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02603809.